Ergotamine tartrate, Caffeine anhydrous
Indications
Ergotamine tartrate, Caffeine anhydrous is used for:
ERGOTAMINE
For use as therapy to abort or prevent vascular headache, e. G. , migraine, migraine variants, or so called "histaminic cephalalgia"
CAFFEINE
For management of fatigue, orthostatic hypotension, and for the short term treatment of apnea of prematurity in infants
For use as therapy to abort or prevent vascular headache, e. G. , migraine, migraine variants, or so called "histaminic cephalalgia"
CAFFEINE
For management of fatigue, orthostatic hypotension, and for the short term treatment of apnea of prematurity in infants
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Ergotamine tartrate, Caffeine anhydrous :
Mechanism of Action
ERGOTAMINE
Ergotamine acts on migraine by one of two proposed mechanisms: 1) activation of 5-ht1d receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache, and 2) activation of 5-ht1d receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release
CAFFEINE
Caffeine stimulates medullary, vagal, vasomotor, and respiratory centers, promoting bradycardia, vasoconstriction, and increased respiratory rate. This action was previously believed to be due primarily to increased intracellular cyclic 3′,5′-adenosine monophosphate (cyclic amp) following inhibition of phosphodiesterase, the enzyme that degrades cyclic amp. It is now thought that xanthines such as caffeine act as antagonists at adenosine-receptors within the plasma membrane of virtually every cell. As adenosine acts as an autocoid, inhibiting the release of neurotransmitters from presynaptic sites but augmenting the actions of norepinephrine or angiotensin, antagonism of adenosine receptors promotes neurotransmitter release. This explains the stimulatory effects of caffeine. Blockade of the adenosine a1 receptor in the heart leads to the accelerated, pronounced "pounding" of the heart upon caffeine intake
Ergotamine acts on migraine by one of two proposed mechanisms: 1) activation of 5-ht1d receptors located on intracranial blood vessels, including those on arterio-venous anastomoses, leads to vasoconstriction, which correlates with the relief of migraine headache, and 2) activation of 5-ht1d receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release
CAFFEINE
Caffeine stimulates medullary, vagal, vasomotor, and respiratory centers, promoting bradycardia, vasoconstriction, and increased respiratory rate. This action was previously believed to be due primarily to increased intracellular cyclic 3′,5′-adenosine monophosphate (cyclic amp) following inhibition of phosphodiesterase, the enzyme that degrades cyclic amp. It is now thought that xanthines such as caffeine act as antagonists at adenosine-receptors within the plasma membrane of virtually every cell. As adenosine acts as an autocoid, inhibiting the release of neurotransmitters from presynaptic sites but augmenting the actions of norepinephrine or angiotensin, antagonism of adenosine receptors promotes neurotransmitter release. This explains the stimulatory effects of caffeine. Blockade of the adenosine a1 receptor in the heart leads to the accelerated, pronounced "pounding" of the heart upon caffeine intake